Clinical Trial Update: Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating letrozole for preventing breast cancer in postmenopausal women who carry BRCA1 or BRCA2 mutations has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hereditary Breast and Ovarian Cancer Syndrome

Drugs mentioned

• Letrozole (letrozole)

Snippet

Sponsor: UNICANCER | Conditions: brca1 Mutation Carrier, brca2 Mutation Carrier | Phase 3 | Status: COMPLETED